JPY 756.0
(-1.82%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 543.94 Million JPY | 53.75% |
2022 | 353.77 Million JPY | 61.18% |
2021 | 219.49 Million JPY | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 192.7 Million JPY | -16.5% |
2024 Q1 | 230.78 Million JPY | 54.08% |
2023 Q3 | 135.27 Million JPY | 0.0% |
2023 Q4 | 149.77 Million JPY | 10.72% |
2023 FY | 543.94 Million JPY | 53.75% |
2022 FY | 353.77 Million JPY | 61.18% |
2021 FY | 219.49 Million JPY | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
KOHJIN BIO CO LTD | 1.28 Billion JPY | 57.653% |
PRISM BioLab Co.,LTD | 576.81 Million JPY | 5.699% |
GNI Group Ltd. | 9.32 Billion JPY | 94.165% |
Linical Co., Ltd. | 2.7 Billion JPY | 79.893% |
Trans Genic Inc. | 2.15 Billion JPY | 74.815% |
MEDINET Co., Ltd. | 1.49 Billion JPY | 63.522% |
Soiken Holdings Inc. | 3.07 Billion JPY | 82.288% |
Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 70.708% |
AnGes, Inc. | 8.9 Billion JPY | 93.89% |
OncoTherapy Science, Inc. | 943.08 Million JPY | 42.323% |
Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 97.165% |
Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -31.708% |
NanoCarrier Co., Ltd. | 975.37 Million JPY | 44.232% |
Carna Biosciences, Inc. | 2.56 Billion JPY | 78.815% |
CanBas Co., Ltd. | 278 Million JPY | -95.663% |
D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | 52.35% |
RaQualia Pharma Inc. | 1.81 Billion JPY | 70.079% |
Chiome Bioscience Inc. | 1.6 Billion JPY | 66.083% |
Kidswell Bio Corporation | 2.37 Billion JPY | 77.088% |
PeptiDream Inc. | 9.68 Billion JPY | 94.385% |
Oncolys BioPharma Inc. | 1.96 Billion JPY | 72.256% |
Ribomic Inc. | 1.1 Billion JPY | 50.805% |
SanBio Company Limited | 4.53 Billion JPY | 88.016% |
Healios K.K. | 3.48 Billion JPY | 84.401% |
BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | 52.895% |
Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 59.239% |
Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 61.243% |
StemRIM | 2.07 Billion JPY | 73.799% |
CellSource Co., Ltd. | 1.96 Billion JPY | 72.297% |
FunPep Company Limited | 313.82 Million JPY | -73.329% |
Kringle Pharma, Inc. | 958.01 Million JPY | 43.222% |
Stella Pharma Corporation | 963.98 Million JPY | 43.574% |
TMS Co., Ltd. | 943.25 Million JPY | 42.333% |
Noile-Immune Biotech Inc. | 1.08 Billion JPY | 50.095% |
Cuorips Inc. | 598.11 Million JPY | 9.058% |
Takara Bio Inc. | 23.9 Billion JPY | 97.725% |
ReproCELL Incorporated | 1.51 Billion JPY | 64.073% |
PhoenixBio Co., Ltd. | 1.18 Billion JPY | 54.059% |
StemCell Institute Inc. | 1.16 Billion JPY | 53.194% |
Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 64.268% |
CellSeed Inc. | 804.93 Million JPY | 32.424% |